HQL
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

abrdn Life Sciences Investors is a closed-end fund that seeks long-term capital appreciation by investing primarily in securities of life sciences companies. The fund invests primarily in equity and related securities, including common stock, preferred stock, convertible debt, limited partnership interests, and warrants, of U.S. and foreign companies principally engaged in the development, production, or distribution of products or services related to scientific advances in life sciences. These life sciences sectors include biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices, supplies, and other healthcare-related subsectors. The fund also invests in companies involved in agriculture and environmental management. The investment strategy targets companies believed to have significant potential for above-average, long-term growth in revenues and earnings, ranging from emerging growth companies at the research and development stage to large, well-known companies with existing products. The fund invests in venture capital and other restricted securities, and in foreign securities, primarily located in Western Europe, Canada, and Japan. The fund may also engage in the purchase and sale of put or call options and financial futures contracts.

Summarised from the fund's shareholder report or prospectus, filed Dec 2025

Industry Asset Management Homepage abrdnhql.com
Sector Financial Services IR page —
Tags
closed-end fund, biotechnology, pharmaceuticals, medical devices, healthcare information technology, agriculture, environmental management, venture capital, emerging growth companies, global equities, abrdn Life Sciences Investors, Restricted Securities, Foreign Securities
Press page —

Metrics

Valuation  
Market cap $ 568.63M
Market cap (USD) $ 568.63M
P/E 2.82
PEG —
P/BV 1.01
P/S 293.35
Discount/premium to NAV -10.6%
P/OCF 17.93
P/FCF 17.93
Dividend yield 9.7%
Turnover / mcap —
Returns  
ROE 17.6%
ROI 16.7%
ROIC -0.49%
Profit margin 4,415.7%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2014
Revenue 1.938M 3.98M 23.524M -103.25M 65.688M — 1.682M 0
Net profit 85.594M 85.296M 22.352M -104.603M 64.531M — 67.279M —
Free cash flow 31.709M — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2014
Share price 15.51 15.08 — — — 17.58 19.87 —
Price performance 12m 0.03 0.21 — — — 0.16 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

abrdn Life Sciences Investors Shares of Beneficial Interest (ticker HQL), listed in United States.

Company History

Date Change Detail
Nov 6, 2023 Renamed TEKLA LIFE SCIENCES INVESTORS → abrdn Life Sciences Investors
Oct 15, 2014 Renamed H&Q LIFE SCIENCES INVESTORS → TEKLA LIFE SCIENCES INVESTORS

ETFs Holding abrdn Life Sciences Investors Shares of Beneficial Interest

ETF Weight in ETF Shares Market value As of
FCEF 1.75% 76,831 $ 1.368M Nov 16, 2026